Research Progress on the Effect of SGLT2 Inhibitors on Cardiac Function in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

急性心肌梗死(acute myocardial infarction, AMI)是一种严重的心血管急症，AMI患者病死率高、预后差，AMI合并糖尿病患者预后更差。钠葡萄糖耦联转运体2 (sodium-glucose linked transporter 2, SGLT2)抑制剂是首个具有心血管保护作用的降糖药，越来越多的临床研究显示SGLT2抑制剂可以改善AMI合并糖尿病患者的心血管预后，目前SGLT2抑制剂在AMI合并2型糖尿病(Type 2 diabetes mellitus, T2DM)的心血管获益机制尚不明确，本文就SGLT2抑制剂在AMI合并T2DM的作用机制、影响心功能指标及预后方面进行综述。Acute myocardial infarction (AMI) is a serious cardiovascular emergency. AMI patients have a high mortality and a poor prognosis, and AMI patients with diabetes have a worse prognosis. Sodium-glucose linked transporter 2 (SGLT2) inhibitors are the first anti-diabetic drugs with cardiovascular protective effects. More and more clinical studies have shown that SGLT2 inhibitors can improve the cardiovascular prognosis of patients with acute myocardial infarction and diabetes. At present, the cardiovascular benefit mechanism of SGLT2 inhibitors in acute myocardial infarction complicated with type 2 diabetes is not clear. This article reviews the mechanism of SGLT2 inhibitors in acute myocardial infarction complicated with type 2 diabetes, and its effect on cardiac function indexes and prognosis.